CUSIP 90400D108 · who reports it, how much, and how much it matters to them
35 of the 720 hedge fund managers we track reported shares of Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) on Form 13F for 30 June 2026. Between them they reported USD 801m. The largest position belongs to RTW Investments, at USD 260m. The manager with the most riding on it is Eagle Health Investments, where it is 4.9% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | RTW Investments2 funds on PPLI.com | USD 260m | 2.2% |
| 2 | Two Sigma Investments35 funds on PPLI.com | USD 121m | 0.1% |
| 3 | D. E. Shaw & Co.15 funds on PPLI.com | USD 58m | 0.0% |
| 4 | Sofinnova Investments1 fund on PPLI.com | USD 57m | 3.0% |
| 5 | Adage Capital Management1 fund on PPLI.com | USD 53m | 0.1% |
| 6 | Voloridge Investment Management6 funds on PPLI.com | USD 41m | 0.2% |
| 7 | Rock Springs Capital Management2 funds on PPLI.com | USD 32m | 1.6% |
| 8 | Eagle Health Investments1 fund on PPLI.com | USD 30m | 4.9% |
| 9 | Millennium Management6 funds on PPLI.com | USD 25m | 0.0% |
| 10 | Palo Alto Investors6 funds on PPLI.com | USD 20m | 2.8% |
| 11 | Sphera Funds Management1 fund on PPLI.com | USD 20m | 2.6% |
| 12 | Renaissance Technologies13 funds on PPLI.com | USD 14m | 0.0% |
| 13 | Squarepoint Ops7 funds on PPLI.com | USD 11m | 0.0% |
| 14 | Walleye Capital8 funds on PPLI.com | USD 11m | 0.0% |
| 15 | Citadel Advisors32 funds on PPLI.com | USD 7m | 0.0% |
| 16 | Atom Investors1 fund on PPLI.com | USD 5.7m | 0.5% |
| 17 | Marshall Wace LLP84 funds on PPLI.com | USD 5.3m | 0.0% |
| 18 | Boothbay Fund Management2 funds on PPLI.com | USD 5.2m | 0.1% |
| 19 | Eversept Partners3 funds on PPLI.com | USD 5.1m | 0.3% |
| 20 | Moore Capital Management7 funds on PPLI.com | USD 4.3m | 0.1% |
| 21 | Brevan Howard Capital Management39 funds on PPLI.com | USD 3.4m | 0.0% |
| 22 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 1.8m | 0.0% |
| 23 | Engineers Gate Manager1 fund on PPLI.com | USD 1.6m | 0.0% |
| 24 | Dafna Capital Management6 funds on PPLI.com | USD 1.6m | 0.3% |
| 25 | Jain Global1 fund on PPLI.com | USD 1.4m | 0.0% |
| 26 | Capital Fund Management S.A.12 funds on PPLI.com | USD 1.1m | 0.0% |
| 27 | Entrypoint Capital1 fund on PPLI.com | USD 860,000 | 0.2% |
| 28 | The Quarry1 fund on PPLI.com | USD 835,000 | 0.1% |
| 29 | Lighthouse Investment Partners190 funds on PPLI.com | USD 694,000 | 0.0% |
| 30 | Aquatic Capital Management3 funds on PPLI.com | USD 560,000 | 0.0% |
| 31 | Capstone Investment Advisors25 funds on PPLI.com | USD 549,000 | 0.0% |
| 32 | Landscape Capital Management4 funds on PPLI.com | USD 223,000 | 0.0% |
| 33 | Verdad Advisers6 funds on PPLI.com | USD 208,000 | 0.2% |
| 34 | Freestone Grove Partners1 fund on PPLI.com | USD 62,139 | 0.0% |
| 35 | Fulcrum Asset Management LLP7 funds on PPLI.com | USD 3,436 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Eagle Health Investments | USD 30m | 4.9% |
| 2 | Sofinnova Investments | USD 57m | 3.0% |
| 3 | Palo Alto Investors | USD 20m | 2.8% |
| 4 | Sphera Funds Management | USD 20m | 2.6% |
| 5 | RTW Investments | USD 260m | 2.2% |
| 6 | Rock Springs Capital Management | USD 32m | 1.6% |
| 7 | Atom Investors | USD 5.7m | 0.5% |
| 8 | Dafna Capital Management | USD 1.6m | 0.3% |
| 9 | Eversept Partners | USD 5.1m | 0.3% |
| 10 | Entrypoint Capital | USD 860,000 | 0.2% |
Ultragenyx Pharmaceutical Inc. trades under the symbol RARE on the Nasdaq. Its CUSIP, the code used on Form 13F, is 90400D108.
35 of the 720 hedge fund managers PPLI.com tracks reported Ultragenyx Pharmaceutical Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by RTW Investments (USD 260m), Two Sigma Investments (USD 121m), D. E. Shaw & Co. (USD 58m), Sofinnova Investments (USD 57m) and Adage Capital Management (USD 53m).
35 managers in our coverage reported it, and between them they run 560 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Eagle Health Investments, where the position was 4.9% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Ultragenyx Pharmaceutical Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.